Dawn Smilek, MD, PhD

Professor

Publications
  1. CALIBRATE: A Phase 2 Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis.
  2. Publisher Correction: The immune cell landscape in kidneys of patients with lupus nephritis.
  3. The immune cell landscape in kidneys of patients with lupus nephritis.
  4. Abatacept Targets T Follicular Helper and Regulatory T Cells, Disrupting Molecular Pathways That Regulate Their Proliferation and Maintenance.
  5. Correlation of hypogammaglobulinaemia with proteinuria, and the relationship between hypogammaglobulinaemia and infection in active lupus nephritis.
  6. ACCLAIM: A randomized trial of abatacept (CTLA4-Ig) for relapsing-remitting multiple sclerosis.
  7. Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort.
  8. Solving the puzzle of autoimmunity: critical questions.
  9. Restoring the balance: immunotherapeutic combinations for autoimmune disease.